Role of food intolerance and effect of protease inhibitor in patients with irritable bowel syndrome (IBS)

Role of food intolerance and effect of protease inhibitor in patients with irritable bowel syndrome (IBS) - Effect of protease inhibitor in patients with irritable bowel syndrome (IBS)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001673

Enrollment

Registered

2009-01-30

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome (IBS)

Interventions

Camostat mesilate 200mg (t.i.d.) will be administrated for 14 days. Rectal barostat measurements will be performed before and the end of the intervention. Placebo (t.i.d.) will be administrated for 14

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who met Rome III diagnostic criteria for IBS

Exclusion criteria

Exclusion criteria: Patients who have severe systemic/ psychological complications, and/or who have histories of any abdominal surgery except appendectomy, and/or who needs to continue any pharmacological treatment during the study

Design outcomes

Primary

Measure	Time frame
Adequate relief (AR) at the end of the intervention	—

Secondary

Measure	Time frame
Symptom severity at the end of the intervention	—

Countries

Japan

Contacts

Public ContactMotoyori Kanazawa

Tohoku University Graduate School of Medicine Department of Behavioral Medicine

m-kanazawa@med.tohoku.ac.jp022-717-7655

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026